Business Description
Regeneron Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US75886F1075
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.89 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | 0.59 | |||||
Interest Coverage | 56.1 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 11.87 | |||||
Beneish M-Score | -2.51 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16 | |||||
3-Year EBITDA Growth Rate | 5 | |||||
3-Year EPS without NRI Growth Rate | 7.9 | |||||
3-Year FCF Growth Rate | 22.8 | |||||
3-Year Book Growth Rate | 32.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | 9.9 | |||||
Future 3-5Y Total Revenue Growth Rate | 9.95 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 50.02 | |||||
9-Day RSI | 61.6 | |||||
14-Day RSI | 65 | |||||
6-1 Month Momentum % | 10.37 | |||||
12-1 Month Momentum % | 39.02 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.27 | |||||
Quick Ratio | 4.51 | |||||
Cash Ratio | 2.94 | |||||
Days Inventory | 520.98 | |||||
Days Sales Outstanding | 148.86 | |||||
Days Payable | 120.63 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.8 | |||||
Shareholder Yield % | 1.54 |
Profitability Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 86.32 | |||||
Operating Margin % | 30.45 | |||||
Net Margin % | 29.45 | |||||
FCF Margin % | 30 | |||||
ROE % | 15.38 | |||||
ROA % | 12.03 | |||||
ROIC % | 19.71 | |||||
ROC (Joel Greenblatt) % | 45.67 | |||||
ROCE % | 14.33 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 31.06 | |||||
Forward PE Ratio | 24.04 | |||||
PE Ratio without NRI | 27.36 | |||||
Shiller PE Ratio | 36.96 | |||||
Price-to-Owner-Earnings | 42.07 | |||||
PEG Ratio | 1.55 | |||||
PS Ratio | 9.15 | |||||
PB Ratio | 4.29 | |||||
Price-to-Tangible-Book | 4.47 | |||||
Price-to-Free-Cash-Flow | 30.54 | |||||
Price-to-Operating-Cash-Flow | 25.31 | |||||
EV-to-EBIT | 26.26 | |||||
EV-to-Forward-EBIT | 20.97 | |||||
EV-to-EBITDA | 23.75 | |||||
EV-to-Forward-EBITDA | 19.75 | |||||
EV-to-Revenue | 8.25 | |||||
EV-to-Forward-Revenue | 7.81 | |||||
EV-to-FCF | 27.49 | |||||
Price-to-Projected-FCF | 1.71 | |||||
Price-to-DCF (Earnings Based) | 0.88 | |||||
Price-to-DCF (FCF Based) | 0.98 | |||||
Price-to-Median-PS-Value | 1.16 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.45 | |||||
Price-to-Graham-Number | 2.33 | |||||
Price-to-Net-Current-Asset-Value | 10.08 | |||||
Price-to-Net-Cash | 36.87 | |||||
Earnings Yield (Greenblatt) % | 3.81 | |||||
FCF Yield % | 3.39 | |||||
Forward Rate of Return (Yacktman) % | 21.89 |